Volume Ramping 1.2M
PharmaGap's Gap107B8 testing shows drop in ascites
2012-02-03 08:49 ET - News Release
This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
Mr. Robert McInnis reports
PHARMAGAP IN VIVO STUDY RESULTS INCLUDE INDICATION OF 80% TO 88% REDUCTION IN ASCITES, 62% REDUCTION IN TUMOUR BURDEN IN OVARIAN CANCER MODELS
PharmaGap Inc. has provided the results from the most recent testing of its cancer drug Gap107B8 in mouse models of human ovarian cancer.
The PharmaGap drug was tested in head to head comparisons against Carboplatin in-vivo using cancer cell lines OCC-1, A2780cp and ES-2. Carboplatin, a chemotherapy drug, is an example of the current standard of care for ovarian cancer. For the first time, proprietary Pharmagap liposomal formulations of Gap107B8 were used. Trends reported with respect to reduction of tumour weight or ascites are expressed relative to the untreated control group.
Ascites reduction in the OCC-1 model using the liposomal formulations ranged from 80-88%. In comparison the Carboplatin control group was found to reduce ascites by 42%. Peritoneal ascites is a significant cause of morbidity in women with ovarian cancer, and is associated with other cancers and gastrointestinal diseases, representing expanded clinical potential. Tumour burden in the OCC-1 model was reduced by 62% with enhanced Gap107B8 whereas Carboplatin reduced tumour burden by 72%.